Pluto Bio

Pluto Biosciences, Inc.Founded in 2020 and headquartered in Golden, US, Pluto Biosciences, Inc. develops a multi-omics platform aimed at improving biological research. The company was founded by Rani Powers, who has a history of involvement in the biotech sector.Pluto Biosciences offers an advanced multi-omics platform designed to facilitate translational discovery in biological research. The platform includes sophisticated bioinformatics tools that enable researchers to analyze and visualize complex biological data, featuring an intuitive no-code interface that streamlines workflows for a range of biological assays including single-cell RNA sequencing (scRNA-seq), RNA-Seq, ChIP-seq, CUT&RUN, and proteomics. The service enhances interdisciplinary collaboration among scientific teams, allowing efficient tracking of experiments, data annotation, and generation of publication-ready visualizations.Pluto Biosciences employs a subscription-based revenue model for access to its multi-omics platform, facilitating direct B2B transactions. Clients can select from various service tiers tailored to their specific research needs, which may include partnerships for custom bioinformatics support. The pricing structure corresponds with the complexity and scale of the analyses required, allowing various institutions to utilize the platform for projects ranging from small academic studies to expansive pharmaceutical research.000 mn, the company plans to invest in the development of AI agents and copilots, expand integrations with R&D tools, build out commercial roles, and accelerate its deployment across various therapeutic areas. Pluto also aims to launch new products that enhance its platform capabilities, targeting expansion into additional global markets by the end of 2026.

1. Seed

   Apr 21, 2025

   Amount

   $3M

   Investors

   Locked

2. Seed

   May 1, 2023

   Amount

   $3.7M

   Investors

   Locked